Lv3
222 积分 2024-11-05 加入
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
2个月前
已完结
Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes
2个月前
已完结
How I treat MDS after hypomethylating agent failure
2个月前
已完结
Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes
2个月前
已完结
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
2个月前
已完结
Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms
3个月前
已完结
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
3个月前
已完结
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
3个月前
已完结
Gastrula‐Premarked Posterior Enhancer Primes Posterior Tissue Development Through Cross‐Talk with TGF‐β Signaling Pathway
4个月前
已完结
Transcriptomic sex differences in postmortem brain samples from patients with psychiatric disorders
6个月前
已完结
皖公网安备34019202002308
